Neil E. Levin, CCN, DANLA
8/1/05 LIKELY USERS: People wanting to support healthy blood flow to the brain and healthy neurological function 1-6,10
Those maintaining normal seasonal immune responses 7-10
KEY INGREDIENTS: 75 mg of Guaranteed Potency Butterbur Root (Petasites hybridus) Extract, min. 15 Sesquiterpenes as Petasines; 200 mg of Feverfew Leaf (Tanacetum parthenium) min. 0.4% Parthenolides
MAIN PRODUCT FEATURES: Butterbur (Petasites hybridus) is a native shrub of Europe, North America, and Asia that has been used by herbalists for centuries. Modern scientific studies have demonstrated that Butterbur supports healthy blood flow to the brain and healthy neurological function.1-6, 10 In addition, Butterbur may help to maintain balanced seasonal immune responses.7-10 In a synergistic base of guaranteed potency Feverfew leaf.11-26
ADDITIONAL PRODUCT USE INFORMATION & QUALITY ISSUES: NOW Butterbur is free of harmful levels of Pyrrolizidine Alkaloids (PAs), the undesirable compounds naturally found in Butterbur, so it is safe to use regularly.
SERVING SIZE & HOW TO TAKE IT: Take one VCap one to three times per day, or as directed by your physician.
COMPLEMENTARY PRODUCTS: Magnesium, Ulcetrol, B-2, B-12, Fish Oil (EPA, DHA), SAM-e, Ginger, Ginkgo Biloba CAUTIONS
SPECIFIC: Do not discontinue use abruptly; taper off use if discontinuing. Discontinue use at least 14 days before surgery or oral surgery. Use with caution if you have ragweed allergies or blood disorders and let your physician know that you plan to use it before you take it. May be contraindicated for pregnant women.
GENERAL: Pregnant and lactating women and people using prescription drugs should consult their physician before taking any dietary supplement. This information is based on my own knowledge and references, and should not be used as diagnosis, prescription or as a specific product claim. Information given here may vary from what is shown on the product label because this represents my own professional experience and understanding of the science underlying the formula and ingredients. When taking any new formula, use common sense and cautiously increase to the full dose over time.
Disclaimer: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. REFERENCES:
1. Diener HC, Rahlfs VW, Danesch U (2004) The First Placebo-Controlled Trial of a Special Butterbur Root Exract for the Preventio of Migraine: Reanalysis of Efficacy Criteria. Eur Neurol 51:89-97.
2. Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A (2004) Petasites hybridus root (butterbur) is an effective preventative treatment for migraine. Neurology 63:2240-2244.
3. Pothmann R, Danesch U (2005) Migraine Preventiuon in Children and Adolescents: Results of an Open Study With a Special Butterbur Root Extract. Headache 45:196-203.
4. Rapaport AM, Bigal ME (2004) Perventive migraine therapy: what is new. Neurol Sci 25:S177-S185.
5. Wu SN, Chen H, Lin YL (2003) The mechanism of inhibitory actions of S-petasin, a sequiterpene of Petasites formosanus, on L-type calcium current in NG108-15 neuronal cells. Planta Med 69(2):118-124.
6. Wang G-J, Wu X-C, Lin Y-L, Ren J, Shum AY-C, Wu Y-Y, Chen C-F (2002) Ca2+ channel blockin effect of iso-S-petasin in rat aoritic smooth muscle cells. Eur J Pharmacol 445(3):239-45.
7. Lee DKC, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ (2003) Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy 33:882-886.
8. Lee DKC, Haggart K, Robb FM, Lipworth BJ (2004) Butterbur, a herbal remedy, confers complementary anti-inflammatory activity in asthmatic patients receiving inhaled corticosteroids. Clin Exp Allergy 34:110-114.
9. Lee DKC, Gray RD, Robb FM, Fujihara S, Lipworth BJ (2004) A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 34:646-649.
10. (No Author) (2001) Petasites hybridus (Butterbur). Alt Med Rev 6(2):207-209.
11. Hayes NA, et al. The Activity of Compounds Extracted from Feverfew on Histamine Release from Rat Mast Cells. J Pharm Pharmacol. Jun1987;39(6):466-70.
12. 2 Groenewegen WA, et al. A Comparison of the Effects of an Extract of Feverfew and Parthenolide, a Component of Feverfew, on Human Platelet Activity In-vitro. J Pharm Pharmacol. 1990;42(8):553-57.
13 Capasso F. The Effect of An Aqueous Extract of Tanacetum parthenium L. on Arachidonic Acid Metabolism by Rat Peritoneal Leucocytes. J Pharm Pharmacol. Jan1986;38(1):71-72.
14. 4 Bejar E. Parthenolide Inhibits the Contractile Responses of Rat Stomach Fundus to Fenfluramine and Dextroamphetamine but not Serotonin. J Ethnopharmacol. Jan1996;50(1):1-12.
15. 5 Prusinski A, Durko A, Niczyporuk-Turek A. [Feverfew as a Prophylactic Treatment of Migraine]. Neurol Neurochir Pol. 1999;33(Suppl 5):89-95.
16. 6 Barsby RW, et al. Feverfew Extracts and Parthenolide Irreversibly Inhibit Vascular Responses of the Rabbit Aorta. J Pharm Pharmacol. Sep1992;44(9):737-40.
17. 7 Pittler MH, Vogler BK, Ernst E. Feverfew for Preventing Migraine (Cochrane Review). Cochrane Database Syst Rev. 2000;(3):CD002286.
18. 8 Pattrick M, et al. Feverfew in Rheumatoid Arthritis: A Double-blind, Placebo Controlled Study. Ann Rheum Dis. 1989;48:547-49.
19. 9 Makheja AM, et al. A Platelet Phospholipase Inhibitor from the Medicinal Herb Feverfew (Tanacetum parthenium). Prostaglandin Leukotri Med. 1982;8:653-60. 20. 12 Drug Identification Number Notification. Drugs Directorate, Therapeutic Products Division, Health Protection Branch, Health Canada . Ottawa , Canada
20. 12 Drug Identification Number Notification. Drugs Directorate, Therapeutic Products Division, Health Protection Branch, Health Canada. Ottawa, Canada.
21. 14 Newall CA, et al. Herbal Medicines: A Guide for Health Care Professionals. London: The Pharmaceutical Press; 1996:119-21.
22. 15 PDR for Herbal Medicines, 2nd ed. Montvale , NJ: Medical Economics Company; 2000:307.
23. 16 Pribitkin ED. Herbal therapy: what every facial plastic surgeon must know. Arch Facial Plast Surg. Apr2001;3(2):
127-32.
24. 17 Schmidt RJ. Plant dermatitis. Compasitae. Clin Dermatol. Apr1986;4(2):46-61.
25. 18 Heck AM, et al. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. Jul2000;57(13): 1221-7.
26. 19 Newall CA, et al. Herbal Medicines: A Guide for Health Care Professionals. London : The Pharmaceutical Press; 1996:119-21. |
